prednisolone + rituximab

Prednisolone + rituximab is a combination of two pharmaceutical agents commonly used in the treatment of hematological malignancies and autoimmune diseases. Prednisolone is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects by modulating gene expression and suppressing immune cell activity. Rituximab is a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, leading to B-cell depletion through mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis. This combination is frequently used in regimens for non-Hodgkin lymphoma (such as R-CHOP) and other B-cell malignancies, where prednisolone helps reduce inflammation, manage side effects like infusion reactions to rituximab, and directly contributes to antitumor activity[3][5][8].

Brand names

Prednisone (for prednisolone, as a related corticosteroid)Rituxan (for rituximab)

Other names

None